Jerome Zeldis

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

ImmuneRegen BioSciences, Inc. researches and develops immunomodulation to improve pulmonary function and stimulating the human immune system. The company is headquartered in Scottsdale, AZ.

Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway.

Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA.

Trek Therapeutics PBC is a for-profit company based in Cambridge, MA. The private company's mission is to develop medicines to treat infectious diseases and make them available to populations in need. The founders of the company, Jerome B. Zeldis and Ann D. Kwong, have collectively participated in developing seven approved antiviral drugs. The company aims to profitably develop safe, novel medicines for infectious diseases at affordable prices. Ann D. Kwong has been the CEO since incorporation.

Central New Jersey Council Boy Scouts of America provides programs, events and opportunities of a lifetime that serve to shape the lives of young men and women in Central and Northern New Jersey. The company was founded in 1995 and is headquartered in Monmouth Junction, NJ.

Arthritis Foundation provides funds research, advocacy and support services for various kinds of arthritis and related diseases. It offers programs and services including aquatic programs, information about treatment breakthroughs, exercise tips for people with the disease and pain management information. Arthritis Foundation is located in Atlanta, GA.

Etubics Corp. develops commercial prophylactic vaccines and immunotherapy products. It offers proprietary immunization platform technology called the etubics platform that develops therapeutic vaccines for colon and breast cancers and preventative vaccines for H1N1 Influenza and HIV. The company was founded by Frank R. Jones in 2003 and is headquartered in Seattle, WA.

Kalytera Therapeutics, Inc. develops non-psychoactive cannabinoid and endocannabinoid-like medicines that address the large unmet market needs. Its preclinical studies support the continued investigation of Kalytera drug candidates in a range of conditions, including bone fracture healing, osteogenesis imperfecta, osteoporosis, and osteoporosis in Prader-Willi syndrome. The company was founded by Seth Yakatan and David Stefansky in 2014 and is headquartered in Manhattan Beach, CA.

Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022.

Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ.

Beyond Air, Ltd. is a clinical-stage medical device and biopharmaceutical company engaging in the development of nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company was founded by Yossef Av-Gay, Amir Avniel, and David Greenberg in May 2011 and is headquartered in Rehovot, Israel.

ViralClear Pharmaceuticals, Inc. manufactures anti-viral drug. The company is headquartered in Westport, CT.

Biond Biologics Ltd. engages in drug discovery and development. It offers cell-internalizing antibody platform that will enable antibody-targeting of intra-cellular immune factors. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel.

Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel.